Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study

Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study

Abstract Brain metastases (BMs) are associated with poor prognosis in epidermal growth factor receptor mutation‐positive (EGFRm) non‐small cell lung cancer (NSCLC). Osimertinib is a third‐generation, irreversible, EGFR‐tyrosine kinase inhibitor that potently and selectively inhibits EGFR‐sensitizing...

Full description

Bibliographic Details
Main Authors: Simon Ekman, Zsolt Cselényi, Andrea Varrone, Aurelija Jucaite, Heather Martin, Magnus Schou, Peter Johnström, Gianluca Laus, Rolf Lewensohn, Andrew P. Brown, Jasper van derAart, Karthick Vishwanathan, Lars Farde
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13500

Internet

https://doi.org/10.1111/cts.13500

Similar Items